Amyloid Therapeutics: Investment Landscape Analysis

Amyloid Therapeutics Investment Landscape

Overview

This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer's disease and related neurodegenerative conditions. [Amyloid-beta](/proteins/amyloid-beta) (Abeta) accumulation is a hallmark pathological feature of Alzheimer's disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. [@clinical2026]

This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.

Pipeline Metrics

Amyloid Therapeutics Investment Landscape

Overview

This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer's disease and related neurodegenerative conditions. [Amyloid-beta](/proteins/amyloid-beta) (Abeta) accumulation is a hallmark pathological feature of Alzheimer's disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. [@clinical2026]

This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.

Pipeline Metrics

| Metric | Value |
|---|---:|
| Total tracked amyloid-related trials | 667 |
| Active trials (recruiting/active/not-yet-recruiting) | 164 (24.6%) |
| Completed trials | 316 (47.4%) |
| Terminated/Withdrawn | 58 (8.7%) |
| Unknown status | 119 (17.8%) |

Trial Status Distribution

Active vs Historical Summary

| Category | Trial Count | Share |
|---|---|---:|
| Active | 164 | 24.6% |
| Recruiting | 99 | 14.8% |
| Not Yet Recruiting | 35 | 5.2% |
| Active Not Recruiting | 30 | 4.5% |
| Historical | 503 | 75.4% |
| Completed | 316 | 47.4% |
| Terminated | 36 | 5.4% |
| Withdrawn | 21 | 3.1% |
| Unknown | 119 | 17.8% |

Phase Distribution

| Phase | Trial Count | Share |
|---|---:|---:|
| Early Phase 1 | 9 | 1.3% |
| Phase 1 | 53 | 7.9% |
| Phase 1/Phase 2 | 11 | 1.6% |
| Phase 2 | 63 | 9.4% |
| Phase 2/Phase 3 | 5 | 0.7% |
| Phase 3 | 36 | 5.4% |
| Phase 4 | 7 | 1.0% |
| Not Applicable/NA | 483 | 72.4% |

Mechanism Breakdown

Amyloid-targeted therapeutics can be categorized by their mechanism of action:

1. Anti-Aβ Monoclonal Antibodies

The largest mechanism category includes antibodies designed to bind and clear amyloid-beta plaques or soluble oligomers.

Key Programs:

• Leqembi (Lecanemab) - Eisai/Biogen - Anti-Aβ protofibril antibody, FDA approved
• [Donanemab](/entities/donanemab) - Eli Lilly - Anti-Aβ plaque antibody, FDA approved
• Crenezumab - Roche/Genentech - Anti-Aβ oligomer antibody
• Gantenerumab - Roche - Anti-Aβ plaque antibody
• Solanezumab - Eli Lilly - Anti-Aβ soluble antibody

2. Aβ Aggregation Inhibitors

Small molecules designed to prevent the formation of or break down amyloid oligomers and plaques.

Key Programs:

• Contursi - Neurokine Therapeutics
• Curcumin derivatives - Multiple researchers
• NC-002 - New Century Therapeutics

3. BACE Inhibitors

[Beta-secretase](/entities/bace1) (BACE) inhibitors block the initial cleavage of [APP](/entities/app-protein) to produce Aβ.

Note: Several BACE inhibitors have failed in late-stage trials due to safety concerns (verubecestat, atabecestat, CNP520).

4. Gamma Secretase Modulators

Modulators of the gamma secretase enzyme that shift Aβ production toward shorter, less aggregation-prone isoforms.

Key Programs:

• GSM-17 - Astellas Pharma
• E2012 - Eisai

5. Aβ Vaccines

Active immunization approaches to induce anti-Aβ antibody production.

Key Programs:

• ACI-35 - AC Immune/Li-Iyonga - Liposome-based [tau](/proteins/tau) vaccine
• ABvac40 - Araclon Biotech - Aβ40 vaccine
• CAD106 - Novartis/Cytos Biotechnology - Aβ immunotherapeutic

6. Aβ Degradation Enhancers

Approaches to enhance the clearance of Aβ through enzymatic degradation or cellular clearance mechanisms.

7. PET Imaging Agents

Diagnostic agents for amyloid plaque imaging:

• Pittsburgh Compound B (PiB) - Research use
• Florbetapir (Amyvid) - FDA approved for PET imaging
• Florbetaben (Neuraceq) - FDA approved for PET imaging
• Flutemetamol (Vizamyl) - FDA approved for PET imaging

Sponsor Landscape

Academic Medical Centers

| Sponsor | Trial Count |
|---|---:|
| Institute for Neurodegenerative Disorders | 11 |
| National Taiwan University Hospital | 10 |
| Chang Gung Memorial Hospital | 9 |
| Washington University School of Medicine | 9 |
| University of Pittsburgh | 8 |
| Massachusetts General Hospital | 8 |

Pharmaceutical Companies

| Sponsor | Trial Count |
|---|---:|
| Eli Lilly and Company | 9 |
| Affiris AG | 8 |
| Pfizer | 6 |
| Cyclo Therapeutics, Inc. | 6 |
| Eisai | 5 |
| Biogen | 4 |
| Roche | 4 |
| Novartis | 3 |
| AstraZeneca | 2 |

Pipeline Gaps and Opportunities

Unmet Needs

Opportunity Areas

Investment Themes

Consolidation Phase

The amyloid therapeutic space has consolidated following the FDA approvals of Leqembi and Donanemab. Investment is shifting toward:

Key Challenges

Cross-Links to Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Amyloid-beta Protein](/proteins/amyloid-beta-protein)
• [Alzheimer's Disease Investment Landscape](/diseases/alzheimers-disease-investment-landscape)
• [Anti-Tau Therapeutics Investment Landscape](/therapeutics/anti-tau-therapeutics)

Clinical Trials

For current clinical trials targeting amyloid-beta and related pathways in Alzheimer's disease, see:

• [Clinical Trials: Alzheimer's Disease](/clinical-trials/alzheimers-disease)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
• [Anti-Tau Therapeutics](/proteins/tau)
• [Tau Protein](/proteins/tau)
• [Beta-Secretase Inhibitors](/genes/ret)

External Links

• [ClinicalTrials.gov - Alzheimer's Disease](https://clinicaltrials.gov/search?cond=Alzheimer+Disease)
• [FDA - Alzheimer's Disease Drug Approvals](https://www.fda.gov/drugs/conditions-we-work-drug-investigational-new-drugs/fda-approves-new-alzheimers-drug)
• [Alzheimer's Association](https://www.alz.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid Therapeutics: Investment Landscape Analysis discovered through SciDEX knowledge graph analysis: